Investment & Partnership Opportunities
Investment Thesis — Three Platforms, One Deep-Tech Portfolio
Aybar Ecotechnologies holds three independent platforms that share one structural characteristic: each removes a cost or a constraint that an established industry currently treats as fixed. We do not manufacture. We license, co-develop, and take equity in commercialization entities, which keeps capital requirements low and puts deployment in the hands of operators who already have the infrastructure.
Protein Purification — Investment Snapshot
A $700B+ Addressable Market
Functional foods ($280B), nutraceuticals ($150B), therapeutic proteins ($227B), plant-based proteins ($40B), and protein purification consumables and services ($19B). One percent penetration is a $7B opportunity. Purification is 50% to 80% of therapeutic protein production cost, and the protocol targets a reduction of up to 65% in that line, with no new equipment required.
Use of funds: industrial pilot deployment, regulatory alignment (GMP, ISO), licensing infrastructure, market development and client onboarding.
Universal Bactericide — Investment Snapshot
Patent-Backed, With Clinical Data in Hand
Granted patents in Mexico (MX 433331, in force to 2040) and Japan (JP 7768769), pending in the United States. A 70-subject comparative clinical study against chlorhexidine 0.12% supports the dental indication. Phase 1 market entry is an oral chewable under DSHEA, which validates commercially while the higher-value respiratory indication goes through clinical development.
Gravity-Modulating Laser — Investment Snapshot
Aerospace, Transportation & Energy Licensing
The highest-risk and highest-ceiling asset in the portfolio. Patent-pending, prototype stage, grounded in published theory dating to 1992. We are seeking OEM partners and development capital to reach a demonstrator, under NDA.
Business Models
Licensing, Joint Ventures & Equity Structures
- Licensing. Protocol or formulation access, priced on production volume.
- Service model. Purification-as-a-service for producers who prefer not to run it in house.
- Joint ventures. Strategic partnerships with ingredient, pharmaceutical, and OEM firms.
- Equity. Aybar Ecotechnologies retains a shareholding in the commercialization entity.
Terms are negotiated per platform and per territory.
Get in Touch
Request an investor brief for a specific platform, or arrange a technical session with our research team, through our contact page.